IP Library › Granted Patent US 12,268,684
Granted Patent B2
US 12,268,684 · App. 18/542,954 · Granted Apr 8, 2025

Pharmaceutical composition for nasal delivery

Inventors: Jonas Sävmarker (Uppsala, SE); Robert Rönn (Uppsala, SE); Andreas Fischer (Uppsala, SE)
Assignee: OREXO AB
A61K31/485A61K9/0043A61K9/1652A61K9/1682
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,684
App. No.
18/542,954
Granted
Apr 8, 2025
Kind
B2
Abstract

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Claims (53)

1. A solid pharmaceutical composition in the form of a spray-dried powder comprising:

a pharmacologically-effective amount of nalmefene or a pharmaceutically-acceptable salt thereof; and

a pharmaceutically-acceptable carrier material comprising a combination of:

(i) a disaccharide selected from the group consisting of maltitol, trehalose, sucralose, sucrose, isomalt, maltose, and lactose; and

(ii) a dextrin;

wherein the composition is essentially free of water and is suitable for nasal delivery of nalmefene or the pharmaceutically-acceptable salt thereof, and the nalmefene or pharmaceutically-acceptable salt thereof is less than about 15% chemically degraded after storage for 3 months at 75% relative humidity and 40° C.

2. The composition as claimed in claim 1 , wherein the lowest measurable glass transition temperature of the composition is at least about 40° C. when measured at a relative humidity of about 35%.

3. The composition as claimed in claim 1 , wherein the particle size distribution of the spray-dried powder includes a Dv(10) that is above about 3 μm.

4. The composition as claimed in claim 1 , wherein the disaccharide comprises lactose and/or trehalose.

5. The composition as claimed in claim 1 , which further comprises an alkyl saccharide.

6. The composition as claimed in claim 5 , wherein the alkyl saccharide comprises a sucrose ester.

7. The composition as claimed in claim 6 , wherein the sucrose ester comprises sucrose monolaurate.

8. The composition as claimed in claim 1 , wherein the dextrin comprises a cyclodextrin or a maltodextrin.

9. The composition as claimed in claim 1 , wherein the carrier material comprises α-D-lactose monohydrate as the disaccharide and one or more of 2-hydroxypropyl-β-cyclodextrin and/or maltodextrin 12DE as the dextrin.

10. The composition as claimed in claim 1 , wherein the dextrin comprises a maltodextrin.

11. The composition as claimed in claim 10 , wherein the carrier material comprises α-D-lactose as the disaccharide, and a maltodextrin.

12. The composition as claimed in claim 1 , wherein the disaccharide is present in an amount of between about 10% and about 30% by weight based on the total weight of the composition.

13. The composition as claimed in claim 1 , wherein the ratio of disaccharide: dextrin is between about 10:1 and about 1:10 by weight.

14. The composition as claimed in claim 1 , wherein the powder has a particle size distribution that includes a volume-based mean diameter within the range of about 10 μm and about 100 μm.

15. A process for the manufacturing of a pharmaceutical composition as defined in claim 1 , wherein said process comprises the steps of:

(a) mixing together in a volatile solvent, nalmefene, or a pharmaceutically-acceptable salt thereof, and pharmaceutically-acceptable carrier materials; and

(b) spray-drying the mixture from step (a) to form the pharmaceutical composition comprising spray-dried particles.

16. A composition obtainable by the process as defined in claim 15 .

17. A nasal applicator device suitable and/or adapted for delivery of the pharmaceutical composition as defined in claim 1 to the nose, which comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

18. A process for the manufacturing of the applicator device as claimed in claim 17 , the process comprising the steps of:

i) mixing together nalmefene or salt thereof and the pharmaceutically-acceptable carrier materials in a volatile solvent;

ii) spray-drying the mixture from step i) to form the pharmaceutical composition comprising spray-dried particles; and

iii) loading the pharmaceutical composition formed in step ii) into the reservoir within or adjunct or attached to said applicator device.

19. A method of treating opioid overdose, which method comprises administering the composition as defined in claim 1 to a subject in need of such treatment.

20. The method as claimed in claim 19 , wherein the composition is administered to said subject by way of an applicator that comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

21. The composition as claimed in claim 1 , which comprises less than about 5% of water.

22. The composition as claimed in claim 1 , which comprises less than about 2% of water.

23. The composition as claimed in claim 1 , which comprises less than about 1% of water.

24. The nasal applicator device as claimed in claim 17 , which is packaged within a container that substantially prevents the ingress of atmospheric water under the storage conditions of 75% relative humidity and 40° C.

25. The nasal applicator device as claimed in claim 17 , which is packaged within a container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

26. A process for the manufacturing of an applicator device as claimed in claim 24 , the process comprising:

i) mixing together nalmefene or salt thereof and the pharmaceutically-acceptable carrier materials in a volatile solvent;

ii) spray-drying the mixture from step i) to form the pharmaceutical composition comprising spray-dried particles;

iii) loading the pharmaceutical composition formed in step ii) into the reservoir within or adjunct or attached to said applicator device; and

iv) loading the applicator device from step iii) into the container that substantially prevents the ingress of atmospheric water.

27. A process for the manufacturing of an applicator device as claimed in claim 25 , the process comprising:

i) mixing together nalmefene or salt thereof and the pharmaceutically-acceptable carrier materials in a volatile solvent;

ii) spray-drying the mixture from step i) to form the pharmaceutical composition comprising spray-dried particles;

iii) loading the pharmaceutical composition formed in step ii) into the reservoir within or adjunct or attached to said applicator device; and

iv) loading the applicator device from step iii) into the container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

28. The composition as claimed in claim 1 , wherein the nalmefene or pharmaceutically-acceptable salt thereof is less than about 10% chemically degraded after storage for 3 months at 75% relative humidity and 40° C.

29. A nasal applicator device suitable and/or adapted for delivery of the composition as defined in claim 28 to the nose, which comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

30. The nasal applicator device as claimed in claim 29 , which is packaged within a container that substantially prevents the ingress of atmospheric water under the storage conditions of 75% relative humidity and 40° C.

31. The nasal applicator device as claimed in claim 29 , which is packaged within a container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

32. The composition as claimed in claim 1 , wherein the nalmefene or pharmaceutically-acceptable salt thereof is less than about 5% chemically degraded after storage for 3 months at 75% relative humidity and 40° C.

33. A nasal applicator device suitable and/or adapted for delivery of the composition as defined in claim 32 to the nose, which comprises, or is adjunct and/or attached to, a reservoir, within which reservoir said composition is contained.

34. The nasal applicator device as claimed in claim 33 , which is packaged within a container that substantially prevents the ingress of atmospheric water under the storage conditions of 75% relative humidity and 40° C.

35. The nasal applicator device as claimed in claim 33 , which is packaged within a container that comprises a material selected from the group of heat-sealed aluminum pouches and thermoformed plastics.

Continuity (5)
Continuation 17172635 · Feb 10, 2021
Continuation 16939717 · Jul 27, 2020
Continuation 16876468 · May 18, 2020
Continuation In Part 16506023 · Jul 9, 2019
Related Publication 20240252485A1 · Aug 1, 2024
References Cited (90)
US 3320952A · Wright · 1967 [cited by examiner]
US 5082669A · Shirai et al. · 1992 [cited by applicant]
US 5702362A · Herold · 1997 [cited by examiner]
US 6398074B1 · Bruna et al. · 2002 [cited by applicant]
US 6938798B2 · Stradella · 2005 [cited by applicant]
US 9724713B2 · Baillet et al. · 2017 [cited by applicant]
US 9895444B2 · Maggio · 2018 [cited by applicant]
US 10653690B1 · Sävmarker et al. · 2020 [cited by applicant]
US 10729687B1 · Sävmarker et al. · 2020 [cited by examiner]
US 10898480B1 · Sävmarker et al. · 2021 [cited by applicant]
US 20030191147A1 · Sherman et al. · 2003 [cited by applicant]
US 20050019411A1 · Colombo et al. · 2005 [cited by applicant]
US 20050042178A1 · Trunk et al. · 2005 [cited by applicant]
US 20150018379A1 · Strang et al. · 2015 [cited by applicant]
US 20150320695A1 · Ryoo et al. · 2015 [cited by applicant]
US 20160045474A1 · Gandhi et al. · 2016 [cited by applicant]
US 20160166503A1 · Crystal et al. · 2016 [cited by applicant]
US 20160235687A1 · Prajapati et al. · 2016 [cited by applicant]
US 20170071851A1 · Keegan et al. · 2017 [cited by applicant]
US 20170319509A1 · Canal et al. · 2017 [cited by applicant]
US 20180092839A1 · Gooberman · 2018 [cited by applicant]
US 20180193332A1 · Loughlin et al. · 2018 [cited by applicant]
US 20190070105A1 · Amancha et al. · 2019 [cited by applicant]
CN 1640402 · 2004 [cited by applicant]
CN 1615867 · 2004 [cited by applicant]
CN 1565451 · 2005 [cited by applicant]
CN 1813739 · 2005 [cited by applicant]
CN 1781479A · 2006 [cited by applicant]
CN 1939358A · 2007 [cited by applicant]
CN 104547220A · 2015 [cited by applicant]
EP 0657176 · 1995 [cited by applicant]
EP 2251038A1 · 2010 [cited by applicant]
JP 2000178184A · 2000 [cited by applicant]
WO 9109592 · 1991 [cited by applicant]
WO 0062757 · 2000 [cited by applicant]
WO 2003061632A1 · 2003 [cited by applicant]
WO 2004054511A2 · 2004 [cited by applicant]
WO 2005065652A1 · 2005 [cited by applicant]
WO 2006085101A2 · 2006 [cited by applicant]
WO 2007024123A1 · 2007 [cited by applicant]
WO 2008033023A2 · 2008 [cited by applicant]
WO WO2009027337A1 · 2009 [cited by examiner]
WO 2009040595A1 · 2009 [cited by applicant]
WO 2009120735A1 · 2009 [cited by applicant]
WO 2010142696A1 · 2010 [cited by applicant]
WO 2011036521A2 · 2011 [cited by applicant]
WO 2015095644A1 · 2015 [cited by applicant]
WO 2016016431A1 · 2016 [cited by applicant]
WO 2016133863A1 · 2016 [cited by applicant]
WO 2016161501A1 · 2016 [cited by applicant]
WO 2017158439A1 · 2017 [cited by applicant]
WO 2017223566A1 · 2017 [cited by applicant]
WO 2018064377A1 · 2018 [cited by applicant]
WO 2018064672A1 · 2018 [cited by applicant]
WO 2018089709A1 · 2018 [cited by applicant]
WO 2018093666A1 · 2018 [cited by applicant]
WO 2018148382A1 · 2018 [cited by applicant]
WO 2019038756A1 · 2019 [cited by applicant]
Adami et al. (Powder Technology 2008;182:105-112) (Year: 2008). [cited by examiner]
Jonas Savmarker Declaration 2023; 11 pages. (Year: 2023). [cited by examiner]
Del Valle, “Cyclodextrins and their Uses: A Review,” Process Biochemistry 39:1033-1046 (2004). [cited by applicant]
Per Gisle Djupesland, “Nasal Drug Delivery Devices: Characteristics and Performance in a Clinical Perspective—A Review,” Drug Deliv. and Transl. Res. 3:42-62 (2013). [cited by applicant]
Fasiolo et al., “Opportunity and Challenges of Nasal Powders: Drug Formulation and Delivery,” Eur. J. Pharm. Sci. 113:2-17 (2018). [cited by applicant]
Florence et al., “The Economic Burden of Prescription Opioid Overdose, Abuse and Dependence in the United States,” Med Care, 54(10):901-906 (2016). [cited by applicant]
Górska et al., “The influence of Trehalose-Maltodextrin and Lactose-Maltodextrin Matrices on Thermal and Sorption Properties of Spray-Dried β-Lactoglobulin-Vitamin D3 Complexes,” J. Therm. Anal. Calorim. 112:429-436 (20… [cited by applicant]
Hahn & Sucker, “Solid Surfactant Solutions of Active Ingredients in Sugar Esters,” Pharm. Res. 6(11):958-960 (1989). [cited by applicant]
Jüptner et al., “Spray Dried Formulations of Nasal Applications-Challenges and Opportunities in Filling and Drug Delivery,” Respiratory Drug Delivery 2:345-348 (2018). [cited by applicant]
Kürti et al., “The Effect of Sucrose Esters on a Culture Model of the Nasal Barrier,” Toxicology in Vitro 26:445-454 (2012). [cited by applicant]
Li et al., “Non-Ionic Surfactants as Novel Intranasal Absorption Enhancers: In Vitro and In Vivo Characterization,” Drug Delivery 23(7):2272-2279 (2016). [cited by applicant]
Middleton et al., “The Pharmacodynamic and Pharmacokinetic Profile of Intranasal Crushed Buprenorphine and Buprenorphine/Naloxone Tablets in Opioid Abusers,” Addiction 106:1460-1473 (2011). [cited by applicant]
Momin et al., “Investigation into Alternative Sugars as Potential Carriers for Dry Powder Formulation of Budesonide,” Biolmpacts 1(2):105-111 (2011). [cited by applicant]
Naini et al., “Physicochemical Stability of Crystalline Sugars and Their Spray-Dried Forms: Dependence upon Relative Humidity and Suitability for Use in Powder Inhalers,” Drug Development and Industrial Pharmacy 24(10):… [cited by applicant]
Pozzoli et al., “Dry Powder Nasal Drug Delivery: Challenges, Opportunities and a Study of the Commercial Teijin Puvlizer Rhinocort Device and Formulation,” Drug Dev. Ind. Pharm. 42(10):1660-1668 (2016). [cited by applicant]
Pozzoli et al., “Development of a Soluplus Budesonide Freeze-Dried Powder for Nasal Drug Delivery,” Drug Dev. Ind. Pharm. 43(9):1510-1518 (2017). [cited by applicant]
Prekupec et al., “Misuse of Novel Synthetic Opioids: A Deadly New Trend,” J. Addic. Med. 11(4):256-265 (2017). [cited by applicant]
Rudd et al., “Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010-2015,” MMWR 65(50-51):1445-1452 (2016). [cited by applicant]
Russo et al., “Primary Microparticles and Agglomerates of Morphine for Nasal Insufflation,” J. Phar. Sci. 95(12):2553-2561 (2006). [cited by applicant]
Sacchetti et al., “Caffeine Microparticles for Nasal Administration Obtained by Spray Drying,” Int. J. Pharm. 242:335-339 (2002). [cited by applicant]
Saokham and Loftsson, “γ-Cyclodextrin,” Int. J. Pharm. 516:278-292 (2017). [cited by applicant]
Szüts and Szabó-Révész, “Sucrose Esters as Natural Surfactants in Drug Delivery Systems—A Mini-Review,” Int. J. Pharm. 433:1-9 (2012). [cited by applicant]
Valdés et al., “Physicochemical Characterization and Cytotoxic Studies of Nonionic Surfactant Vesicles using Sucrose Esters as Oral Delivery Systems,” Colloids and Surfaces B: Biointerfaces 117:1-6 (2014). [cited by applicant]
Vengerovich et al., “Analysis of the Efficiency of Microencapsulated Sustained-Release Form of Naloxone on the Experimental Model of Fentanyl Poisoning,” Bull. Exp. Biol. Med 163(6):737-741 (2017). [cited by applicant]
Zhao et al., “Hydroxypropyl-β-Cyclodextrin as Anti-Hygroscopicity Agent Inamorphous Lactose Carriers for Dry Powder Inhalers,” Powder Technology 2-11 (2018). [cited by applicant]
Barnett et al., “Therapeutic Reviews,” Journal of Pain and Sumptom Management 47(2):341-352 (2014). [cited by applicant]
Santosh Thorat, “Formulation and Product Development of Nasal Spray: An Overview,” SJAMS 4(8D):2976-2985 (2016). [cited by applicant]
Oliveira et al., Spray Drying of Food and Herbal Products, Chapter 5 pp. 113-156 (2010). [cited by applicant]
Piyush Mehta, “Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering,” Journal of Drug Delivery vol. 2018 19 Pages (2018). [cited by applicant]
Dowd et al., “Pharmacology and Therapeutics for Dentistry,” p. 319 (2010). [cited by applicant]
Amaro et al., “Co-spray Dried Carbohydrate Microparticles: Crystallisation Delay/Inhibition and Improved Aerosolization Characteristics Through the Incorporation of Hydroxypropyl-β-cyclodextrin With Amorphous Raffinose … [cited by applicant]
Pharmaceutical Dosage Forms-Tablets 2016: p. 92 [online] retrieved on Dec. 12, 22 from: https://www.google.com/books/edition/Pharmaceutical_Dosage_Forms_ Tablets/JP _LBQAAQBAJ?hl=en&gbpv=0; 1 page) (Year: 2016). [cited by applicant]
Cited By (9)
US 12,414,916 US 12,502,498 US 12,605,517 US 12,653,778 US 12,653,972 US 12,661,315 US 12,678,404 US 12,678,574 US 12,728,092